tbuckley/cabot-search huggingface dataset:
Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma
Authors: Irene M. Ghobrial, Jacob P. Laubach, Kenneth H. Shain, Rachid Baz, Erica N Boswell, Patrick M Henrick, Abdel Kareem Azab, Courtney Hanlon, Stacey Chuma, Houry Leblebjian, Kimberly Noonan, Megan H. MacNabb, Diane Warren, Philippe Armand, Claudia E. Paba-Prada, Nikhil C. Munshi, Robert L Schlossman, Kenneth C. Anderson, Paul G. Richardson
Journal: Blood (2014)
Endosulfan Exposure Disrupts Pheromonal Systems in the Red-Spotted Newt: A Mechanism for Subtle Effects of Environmental Chemicals
Authors: Daesik Park, Steven C. Hempleman, Catherine R. Propper
Journal: Environmental Health Perspectives (2001)

Because chemicals introduced into the environment by humans can affect both long-term survivorship and reproduction of amphibians, discovering the specific mechanisms through which these chemicals act may facilitate the development of plans for amphibian conservation. We investigated the amphibian pheromonal system as a potential target of common environmental chemicals. By treating female red-spotted newts, Notophthalmus viridescens, to a commonly used insecticide, endosulfan, we found that the pheromonal system is highly susceptible to low-concentration exposure. The impairment of the pheromonal system directly led to disrupted mate choice and lowered mating success. There were no other notable physiologic or behavioral changes demonstrated by the animals at the insecticide concentrations administered. Our findings suggest that the amphibian pheromonal system is one of the systems subject to subtle negative effects of environmental chemicals.
Postexercise electrocardiogram in arteriosclerotic heart disease. Its value in diagnosis and prognosis
Authors: G. P. Robb
Journal: JAMA (1967)

An evaluation of the electrocardiographic exercise test in the diagnosis and prognosis of latent arteriosclerotic heart disease was made using improved methods of performance and interpretation. The evaluation was based on 2,224 male applicants for life insurance given the test. A long-term follow-up of these cases disclosed: Ischemic ST segment depression after exercise is pathognomonic of coronary insufficiency for all practical purposes. The amount of ischemic ST depression indicates the degree of the insufficiency and the prognosis. Ischemic response involving multiple leads has a worse prognosis than that involving one lead. In the vast majority of cases, a nonischemic response—ST junction depression, negative response, or T-wave change—excludes latent coronary insufficiency of significant degree. Preexercise T-wave abnormality due to coronary disease is distinguished by an ischemic response. In this study, the postexercise electrocardiogram gave more reliable evidence of latent or silent coronary disease than did the medical history. No adverse effect resulted from the test.
Surgical Bacteriology.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DELIRIUM IN PNEUMONIA.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study
Authors: F. Maindrault-Goebel, G. Lledo, B. Chibaudel, L. Mineur, T. Andre, M. Bennamoun, M. Mabro, P. Artru, C. Louvet, A. De Gramont
Journal: Journal of Clinical Oncology (2006)

3504 Background: The OPTIMOX1 study (JCO 2006) has shown that the strategy of 6 cycles of FOLFOX7 followed by maintenance therapy and FOLFOX reintroduction was as active and better tolerated than FOLFOX4 until progression. The aim of the OPTIMOX2 study was to evaluate a complete stop of chemotherapy after 6 bimonthly cycles of FOLFOX. Methods: Initially planned as a phase III study, OPTIMOX2 was downgraded to a large phase II study since the availability of bevacizumab. Patients (pts) were randomized between an OPTIMOX1 arm: 6 cycles of FOLFOX7 followed by LV5FU until progression and reintroduction of FOLFOX7, and the OPTIMOX2 arm: 6 cycles of FOLFOX7, complete stop of chemotherapy and reintroduction of FOLFOX7 before the tumor progression reached the baseline measures. Results: 187/200 planned pts were included between Feb 2004 and Nov 2005. Response rates were (OPTIMOX1 arm/OPTIMOX2 arm): CR 2%/2%, PR 54%/51%, stable 24%/33%, progression 11%/7%, non assessable 9%/7%. Median PFS were (OPTIMOX1 arm/OPTIMOX2 arm) 36/28 weeks (p=.01), PFS in responders 41/30 weeks (p=.001), PFS in stable patients 34/26 weeks (p=.23). Median duration of disease control (DDC), addition of PFS of first FOLFOX7 administration plus PFS of FOLFOX reintroduction if no progression at first evaluation, was 41 weeks in the OPTIMOX1 arm and 36 in the OPTIMOX2 arm, p=.17. Median duration of chemotherapy-free interval in the OPTIMOX2 arm was 25 weeks (5.7 months). Conclusions: Maintenance LV5FU therapy prolongs PFS. The quality of life of almost 6 months CFI can balance a small advantage in DDC for maintenance therapy. Our next goal is to evaluate maintenance therapy with targeted agents alone. [Table: see text]
有关汗液分泌的神经控制:综述
Authors: Y. Hu, C. Converse, M.C. Lyons, W.H. Hsu
Journal: British Journal of Dermatology (2018)

人体有四百万个汗腺,这些汗腺可分为两类:外分泌腺(大约占人体汗腺的 90%)和顶泌腺。20 世纪 80 年代,科学家发现了第三类汗腺,即大小汗腺。但是,这在一些科学家中存在争议并且缺乏充分认识。汗腺的作用是维持体温、排出汗液并对情绪压力作出反应。神经递质在人体细胞(包括神经元)之间充当化学信使传递信号,人体中枢神经系统通过该神经递质向外周神经系统发送信号,以控制汗液分泌(参与体温调节并对情绪压力作出反应)。这表示,人体神经系统对于汗液分泌是至关重要的。该综述探讨了汗液分泌方面的内容,尤其是关于汗液分泌的神经(神经系统)控制,以及神经递质触发汗液分泌的机理。来自美国的研究人员还探讨了与神经异常有关的汗液分泌障碍,比如多汗症(出汗过多)以及少汗症(出汗少)。该研究还概述了可能适合此类障碍的治疗方案及其有效性。
Clofibrate-Induced Gene Expression Changes in Rat Liver: A Cross-Laboratory Analysis Using Membrane cDNA Arrays
Authors: Valerie A. Baker, Helen M. Harries, Jeff  F. Waring, Colette M. Duggan, Hong A. Ni, Robert A. Jolly, Lawrence W. Yoon, Angus T. De Souza, Judith E. Schmid, Roger H. Brown, Roger G. Ulrich, John C. Rockett
Journal: Environmental Health Perspectives (2004)
A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix
Authors: A. Dueñas-González, J. J. Zarba, J. C. Alcedo, P. Pattarunataporn, S. Beslija, F. Patel, L. Casanova, H. Barraclough, M. Orlando
Journal: Journal of Clinical Oncology (2009)

CRA5507 Background: Cervical cancer is the second-most common cancer among women worldwide, in both incidence and mortality. Current standard therapy for locally advanced disease consists of concurrent Cis and external-beam radiation (XRT). This multicenter, open-label, randomized, phase III trial aimed to improve outcomes, capitalizing on the synergistic activity of Gem, Cis, XRT, and the potential value of adjuvant therapy. Methods: Eligible patients (pts) with bulky stage IIB to IVA, 18–70 years of age, chemotherapy- and radiotherapy-naive, with a Karnofsky Performance Status score ≥70, were randomized to Arm A: Cis 40 mg/m2 followed by Gem 125 mg/m2 weekly × 6 doses with concurrent XRT (50.4 Gy: in 28 fractions: 1.8 Gy/day, 5 days/week), followed by brachytherapy (brachy) (30–35 Gy) and then 2 adjuvant 21-day cycles of Gem (1,000 mg/m2 on Days 1 and 8) plus Cis (50 mg/m2 on Day 1); or Arm B: Cis 40 mg/m2 weekly × 6 doses with concurrent XRT followed by brachy, given as in Arm A. Primary endpoint was progression-free survival (PFS) at 3 years, compared between arms using Kaplan-Meier methods and a Z-statistic. Results: 515 pts were enrolled between 5/02 and 3/04 (259 pts Arm A, 256 pts Arm B). Median age was 46 years; stage IIB/IIIB/IVA in 61/37/2% of pts. Compliance in the concurrent and brachy phase was &gt;90% for both arms; adjuvant cycles were completed by &gt;75% of pts in Arm A. PFS at 3 years was 74% in Arm A compared to 65% in Arm B, resulting in a statistically significant improvement (p = 0.029). Overall survival (log-rank p = 0.0224) and time to progressive disease (log-rank p = 0.0008) were also significantly improved. Significantly more pts in Arm A experienced grade 3/4 toxicities (86.5%), compared to pts in Arm B (46.3%; Fisher's p &lt; 0.001). In Arm A, 2 pts died due to causes probably related to treatment compared to 0 pts in Arm B. Conclusions: This novel regimen of concurrent Gem plus Cis and XRT followed by brachy and adjuvant Gem plus Cis significantly improved outcomes in pts with locally advanced carcinoma of the cervix, at the expense of increased but acceptable toxicity, compared to the current standard of care. [Table: see text]
Outdoor Particulate Matter Exposure and Lung Cancer: A Systematic Review and Meta-Analysis
Authors: Ghassan B. Hamra, Neela Guha, Aaron Cohen, Francine Laden, Ole Raaschou-Nielsen, Jonathan M. Samet, Paolo Vineis, Francesco Forastiere, Paulo Saldiva, Takashi Yorifuji, Dana Loomis
Journal: Environmental Health Perspectives (2014)

Background: Particulate matter (PM) in outdoor air pollution was recently designated a Group I carcinogen by the International Agency for Research on Cancer (IARC).This determination was based on the evidence regarding the relationship of PM 2.5 and PM 10 to lung cancer risk; however, the IARC evaluation did not include a quantitative summary of the evidence.oBjective: Our goal was to provide a systematic review and quantitative summary of the evidence regarding the relationship between PM and lung cancer.Methods: We conducted meta-analyses of studies examining the relationship of exposure to PM 2.5 and PM 10 with lung cancer incidence and mortality.In total, 18 studies met our inclusion criteria and provided the information necessary to estimate the change in lung cancer risk per 10-μg/m 3 increase in exposure to PM.We used random-effects analyses to allow between-study variability to contribute to meta-estimates.results: The meta-relative risk for lung cancer associated with PM 2.5 was 1.09 (95% CI: 1.04, 1.14).The meta-relative risk of lung cancer associated with PM 10 was similar, but less precise: 1.08 (95% CI: 1.00, 1.17).Estimates were robust to restriction to studies that considered potential confounders, as well as subanalyses by exposure assessment method.Analyses by smoking status showed that lung cancer risk associated with PM 2.5 was greatest for former smokers [1.44 (95% CI: 1.04, 1.22)], followed by never-smokers [1.18 (95% CI: 1.00, 1.39)], and then current smokers [1.06 (95% CI: 0.97, 1.15)].In addition, meta-estimates for adenocarcinoma associated with PM 2.5 and PM 10 were 1.40 (95% CI: 1.07, 1.83) and 1.29 (95% CI: 1.02, 1.63), respectively.conclusion: The results of these analyses, and the decision of the IARC Working Group to classify PM and outdoor air pollution as carcinogenic (Group 1), further justify efforts to reduce exposures to air pollutants that can arise from many sources.
Bernardino Ramazzini.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infectious Diseases
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early experiences with azathioprine in ulcerative colitis; a note of caution
Authors: G. E. Bowen
Journal: JAMA (1966)

Several informative studies have described the use of immunosuppressive agents in diseases classified as auto-immune in pathogenesis. Dameshek and Schwartz<sup>1,2</sup>have shown that certain antimetabolities are capable of creating a drug-induced immunologic tolerance that theoretically should reduce the activity of diseases produced by altered immune mechanisms. Various immunosuppressive agents have been observed experimentally to reduce or prevent the primary<sup>3,4</sup>and secondary<sup>5</sup>immune response in animals, decrease the level of γ-globulin,<sup>6</sup>inhibit immediate and delayed hypersensitivity,<sup>7</sup>and to induce a prolonged functionalsurvival state in homograft material.<sup>8,9</sup>Furthermore, various clinical trials<sup>10-13</sup>suggest potential beneficial effects of immunosuppressive agents in diseases such as systemic lupus erythematosus, auto-immune hemolytic anemia, hyperglobulinemia purpura, erythema nodosum, and polyarteritis nodosa, identified with immunologic mechanisms. One of these agents, azathioprine (Imuran)<sup>14,15</sup>has shown sufficient promise to justify a clinical trial in ulcerative colitis. Azathioprine is a heterocyclic derivative of 6-mercaptopurine
CARCINOMATOUS OSTEOMALACIA.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nutritional Immunity
Authors: Eugene D. Weinberg
Journal: JAMA (1975)

WITHIN the past half century, the doctrine of the biochemical unity of living matter has become well established. Metabolic pathways as well as methods of storage, transfer, and use of energy and of genetic information are found to have strong commonality in the cells of microorganisms, plants, and animals. As a consequence, similar kinds of organic and inorganic components are used in the building of protoplasm by the three forms of life. Moreover, the quantities of inorganic nutrilites needed for cell replication are quite similar. For example, to achieve maximal growth, cultures of cells of microorganisms, plants, and animals each require approximately 1μM solution of iron, 1 mM solution of phosphorus, and 1 mM solution of magnesium. <h3>Immunity</h3> In view of these similarities, it is remarkable that plants and animals have been able to develop, during evolution, methods for keeping many of their tissues and organs free of microbial invaders.
THE NEW YORK HOSPITAL FORMULARY— A VENERABLE AMERICAN INSTITUTION
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Books Received
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sinusitis
Authors: R A Friedman, J P Harris
Journal: Annual Review of Medicine (1991)

Paranasal sinusitis is one of the most common diseases treated in outpatient centers across the United States. Improved bacterial culture techniques have revealed the variety of pathogens involved in acute and chronic sinusitis. The growing numbers of antibiotic-resistant bacterial strains and of immunocompromised patients have changed the clinical face of sinusitis. New diagnostic modalities, including magnetic resonance imaging, are facilitating more rapid and accurate disease detection.
“Plasma pro-surfactant protein B and lung function decline in smokers.” Janice M. Leung, John Mayo, Wan Tan, C. Martin Tammemagi, Geoffrey Liu, Stuart Peacock, Frances A. Shepherd, John Goffin, Glenwood Goss, Garth Nicholas, Alain Tremblay, Michael Johnston, Simon Martel, Francis Laberge, Rick Bhatia, Heidi Roberts, Paul Burrowes, Daria Manos, Lori Stewart, Jean M. Seely, Michel Gingras, Sergio Pasian, Ming-Sound Tsao, Stephen Lam and Don D. Sin, for the Pan-Canadian Early Lung Cancer Study …
Journal: European Respiratory Journal (2016)